Monoglyceride/lactate ester permeation enhancer for oxybutnin

Patent 5900250 Issued on May 4, 1999. Estimated Expiration Date:

April 30, 2018. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.

Abstract Claims Description Full Text

Patent References

3472931

3527864

3551554

3598122

3598123

3731683

3797494

3896238

3903256

Dermatological compositions
Patent #: 3952099
Issued on: 04/20/1976
Inventor: Smith

More ...

Inventors

Assignee

ALZA Corporation

Application

No. 070492 filed on 04/30/1998

US Classes:

424/448, Pressure sensitive adhesive means424/449, Transdermal or percutaneous514/946PENETRANT OR ABSORBENT (ENHANCES PENETRATION INTO SUBJECT TREATED)

Examiners

Primary: Brouillette, Gabrielle

Attorney, Agent or Firm

Rafa; Michael J., Sabatine; Paul, Stone; Steven F.

Foreign Patent References

902605 BE. 09/12/1985
0250125 EP. 06/12/1987
0295411 EP 05/12/1988
0295411 EP 12/12/1988
0368339 EP 11/12/1989
0368409 EP. 05/12/1990
0368339 EP 05/12/1990
0431942 EP 12/12/1990
1001949 GB. 07/12/1962
9210231 WO. 06/12/1992
92/20377 WO. 11/12/1992
WO9220377 WO 11/12/1992

International Class

A61F 013/02

Abstract

A composition of matter for application to a body surface or membrane to administer oxybutynin by permeation through the body surface or membrane, the composition comprising, in combination, the oxybutynin to be administered, in a therapeutically effective amount; and a permeation-enhancing mixture comprising a monoglyceride or a mixture of monoglycerides, and a lactic ester or a mixture of lactate esters; present in specific concentrations.

Other References

Keshary et al., "Development of Transdermal Delivery Systems for Oxybutynin In-Vivo Bioavailability" Pharm. Res., (NY) 8 (10 Suppl.) 1991, p. 5205
1992 Physicians Desk Reference, pp. 1332-1333
Idson, "Percutanoaus Absorption," J. Pharm. Sci., vol. 64, No. 66, Jun. 1975 pp. 901-924
Abstract of Japanese Patent No. JP 04273818-A, dated Feb. 28, 1991
Abstract of Japanese No. JP04099719 dated Mar. 31, 1992
Abstract of Japanese Patent No. JP 04266821 dated Sep. 22, 1992
Tetrahedron Letters No. 20, pp. 1609-1612. Pergammon Press (1971). Hester, Jackson B., Duchamp, David J. Chidester, A Synthetic Approach to New 1,4-Benzodiazepine Dervatives
J. of Med. Chem., 1977, V. 20, p. 1694, Walser, Armin and Zenchoff, Gladys, "Quinazolines and 1,4-Benzodiazepines. 81.' s-Triazolo4m3-a!1,4!benzodiazepines by Oxidative Cyclization of Hydrazones"
Current Ther. Res. Jun. 1976, V. 19, pp. 661-668, Nakajima; Take; Moriya; Saji; Yui; nagawa, Pharmacological Studies on New Potent Central Depressants; 8-Chloro-6-Phenyl-4H-s-Triazlo
Naunyn-Schmiedeberg's Arch. Pharmacol. 301, pp. 157-161 (1978), Sethy, Vimala H. Sethy, "Effect of Hypnotic and Anxiolytic Agents on regional Concentration of Acetylcholine in Rat Brain"
Current Therapeutic Res., V. 19, No. 6, Jun. 1976, pp. 661-668, Fabre, Louis F., Jr., Pilot Open Label Study with Alprozolam (U31;889) in Outpatients with Neurotic Depression Alprozolam (U31;899) in outpatients with Neurotic Depression
J. Clin. Psychiatry 42:9, Sep. 1981 pp. 347-351, Cohn, Jay B., "Multicenter Double-Blind Efficacy and Safety Study Comparing Alprazolam, Diazepam and Placebo in Clinically Anxious Patients"
J. Clin. Psychiatry, 44, 45 (1983) pp. 45-47, Abernethy, Greenlatt, Divol and Shader, "Pharmacokinetics of Alprazolam"
Pharmacotherapy, 2, (1982), pp. 243-254, Fawcett and Kravitz, "Alprozolam: Pharmacokinetics, Clinical Efficacy, and Mechanism of Action"
CRC Critical Review and Therapeutic Drug Carrier Systems, vol. 4, Issue 1 (1987) pp. 13-37 Knepp, Hadgraft, Guy, "Transdermal Drug Delivery: Problems and Possibilities"
J. of Pharmaceutical Sciences, V. 64, No. 6, Jun. 1975, pp. 901-924, Idson, "Percutaneous Absorption"
J. of Pharmacology & Experimental Therapeutics, 1992 V. 256, No. 2, pp. 562-567, Noronha-Blob and Kachur, Enantiomers Oxybutynin: In Vitro Pharmacological Characterization at M₁, M₂, M₃ Muscarinic etc
J. of Pharmacology & Experimental Therapeutics, 1991 V. 247, No. 3, pp. 867-872, Kachur et al., "R & S Enantiomers of Oxybutynin: Pharmacological Effects in Guinea Pig Bladder & Intestine